Cargando…

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

BACKGROUND: Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute myeloid leukemia (r/r AML), but identification of this subset remains difficult. METHODS: To search for biomarkers o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Woonbok, Kelly, Andrew D., Kropf, Patricia, Fung, Henry, Jelinek, Jaroslav, Su, Xiang Yao, Roboz, Gail J., Kantarjian, Hagop M., Azab, Mohammad, Issa, Jean-Pierre J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647096/ https://www.ncbi.nlm.nih.gov/pubmed/31331399 http://dx.doi.org/10.1186/s13148-019-0704-3

Ejemplares similares

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
por: Jelinek, Jaroslav, et al.
Publicado: (2011)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies
por: Xu, Cong, et al.
Publicado: (2017)

Core binding factor acute myelogenous leukemia-2021 treatment algorithm
por: Borthakur, Gautam, et al.
Publicado: (2021)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
por: Topp, Max S., et al.
Publicado: (2020)

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Chen, Joseph, et al.
Publicado: (2020)

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2021)

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
por: Kantarjian, Hagop M., et al.
Publicado: (2023)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
por: Albany, Costantine, et al.
Publicado: (2016)

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
por: Stock, Wendy, et al.
Publicado: (2020)

Demethylator phenotypes in acute myeloid leukemia
por: Kelly, Andrew D., et al.
Publicado: (2018)

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
por: Rambaldi, Alessandro, et al.
Publicado: (2019)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia
por: Sobash, Philip T., et al.
Publicado: (2020)

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
por: Ravandi, Farhad, et al.
Publicado: (2023)

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
por: Kreitman, Robert J., et al.
Publicado: (2018)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
por: Topp, Max S., et al.
Publicado: (2021)

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
por: Jueliger, Simone, et al.
Publicado: (2016)

Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report
por: Dorantes-Acosta, Elisa, et al.
Publicado: (2009)

The role of early molecular predictor in transplant-eligible chronic myelogenous leukemia
por: Kim, Sung-Hyun
Publicado: (2017)

Hemophagocytic Lymphohistiocytosis and Relapsing Polychondritis with Acute Myelogenous Leukemia: Case Report and Review of the Literature
por: Alsaid, Hamza M., et al.
Publicado: (2020)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
por: Guzman, Monica L., et al.
Publicado: (2014)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
por: Wong, Jonathan, et al.
Publicado: (2022)

Identification of Novel Tumor Markers in Prostate, Colon and Breast Cancer by Unbiased Methylation Profiling
por: Chung, Woonbok, et al.
Publicado: (2008)

Identification of Novel Tumor Markers in Prostate, Colon and Breast Cancer by Unbiased Methylation Profiling
por: Chung, Woonbok, et al.
Publicado: (2008)

Acute promyelocytic leukemia current treatment algorithms
por: Yilmaz, Musa, et al.
Publicado: (2021)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b24s82bqdjqlqlbvut8ae50mbr